普洛药业子公司取得头孢地尼干混悬剂药品注册证书

Core Viewpoint - Prolo Pharmaceutical (000739) announced that its wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] Group 1: Product Information - Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic [1] - It is indicated for the treatment of mild to moderate infections in pediatric patients caused by specified sensitive strains of microorganisms under certain conditions [1] Group 2: Indications - The product is effective against acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - It is also indicated for pharyngitis/tonsillitis caused by Streptococcus pyogenes [1] - Additionally, it treats uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]